Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: The significance of apolipoprotein B to apolipoprotein AII ratio

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 6, 2000, Pages 529-538

  Cerne, D ^a   Ledinski, G ^a   Kager, G ^a   Greilberger, J ^a   Wang, X ^a   Jurgens, G ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Apoplipoproteins; Bilirubin; Carotid atherosclerosis; Coronary atherosclerosis; Creactive protein; Oxidized LDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; AUTOANTIBODY; BILIRUBIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIALIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; ECHOGRAPHY; FAMILY HISTORY; HUMAN; ISCHEMIA; LABORATORY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0033869938     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.078     Document Type: Article

References (64)

1. Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction
2. Apolipoproteins and coronary artery disease
3. The significance of high levels of lipoprotein(a) compared with established risk factors in premature coronary artery disease: Differences between men and women
4. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease
5. The oxidation hypothesis of atherosclerosis
6. Methods for assessing lipid and lipoprotein oxidation
7. Autoantibody against oxidized LDL and progression of carotid atherosclerosis
8. Antibody against oxidized low-density lipoprotein predicting myocardial infarction
9. Desialylated low density lipoprotein - Naturally occuring modified lipoprotein with atherogenic potency
10. Multiple modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization
11. Carbohydrate composition of protein and lipid components in sialic-rich and -poor low density lipoproteins from subjects with and without coronary artery disease J Lip Res
12. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells
13. Low-density lipoprotein modification occurring in human plasma. Possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification
14. Bilirubin is an antioxidant of possible physiological importance
15. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than trolox
16. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation
17. Association of low serum concentration of bilirubin with increased risk of coronary artery disease
18. Higher serum bilirubin is associated with decreased risk of early familial coronary artery disease
19. The pathogenesis of atherosclerosis: A perspective for the 1990s
20. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
21. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial
22. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
23. Coronary arteriography
24. Protein measurement with the Folin phenol reagent
25. ELISA of IgG Antibody to oxidized low density lipoprotein: Effect of blocking buffer and method of data expression
26. Intimal medial thickening of common carotid artery as indicator of coronary artery disease
27. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study
28. High-density lipoprotein particles are large in patients with variant angina
29. Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease
30. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease
31. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study
32. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction
33. Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery
34. HDL subparticles and coronary artery disease in NIDDM
35. Multiple abnormalities of high density lipoprotein in patients with type II diabetes and coronary disease
36. Apolipoprotein A-I containing lipoproteins in coronary artery disease
37. Lipoproteins and apolipoproteins in the young and familial risk of coronary atherosclerosis
38. Lp(a) and the risk of coronary heart disease
39. Cholesterol efflux, cholesterol esterification and cholesteryl ester transfer by Lp A-I and Lp A-II in native plasma
40. The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle
41. Interaction of apolipoprotein A-II with recombinant HDL containing egg phosphatidylcholine, unesterified cholesterol and apolipoprotein A-I
42. Influence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and AII
43. ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion
44. Overexpression of apolipoprotein All in transgenic mice converts high density lipoproteins to proinflammatory particles
45. The properties of HDL in genetically engineered mice
46. Distribution patterns of apolipoproteins A1, A2, and B in the wall of atherosclerotic vessels
47. Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: Results from the NHLBI Family Heart Study
48. Lipoprotein(a) as a risk factor for ischemic heart disease: Metaanalysis of prospective studies
49. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
50. Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina
51. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
52. C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
53. Plasma sialic acid and coronary artery atheromatous load in patients with stable chest pain
54. Coronary C-reactive protein distribution: Its relation to development of atherosclerosis
55. Association of smoking and low serum bilirubin antioxidant concentrations
56. Relationship between bilirubin, apolipoprotein B, and coronary artery disease
57. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease
58. Immunodetection of modified lipoproteins in plasma and arterial walls of patients with coronary heart disease
59. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis
60. Sialic acids and the metabolism of low density lipoprotein
61. LDL sialic acid content in patients with coronary artery disease
62. All low density lipoprotein particles are partially desialylated in plasma